Reaction
Chorioretinitis reporting signals
As of the last recalculation, Chorioretinitis appears in 635 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is FARICIMAB (PRR 154.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Faricimab | 36 | 154.3 | 155.0 |
| Daptomycin | 11 | 39.8 | 39.8 |
| Anti-Thymocyte Globulin (Rabbit) | 9 | 37.1 | 37.1 |
| Rifampicin | 10 | 32.9 | 32.9 |
| Aflibercept | 29 | 31.9 | 31.9 |
| Encorafenib | 9 | 30.2 | 30.2 |
| Valganciclovir Hydrochloride Powder, | 11 | 30.1 | 30.1 |
| Amphotericin B | 11 | 29.3 | 29.3 |
| Atropine Sulfate | 8 | 24.6 | 24.6 |
| Adalimumab-Fkjp | 32 | 23.8 | 23.8 |
| Pyrazinamide | 6 | 21.1 | 21.1 |
| Isoniazid | 10 | 20.5 | 20.6 |
| Voriconazole Injection | 13 | 20.0 | 20.0 |
| Iron Sucrose | 5 | 17.3 | 17.3 |
| Remdesivir | 6 | 14.9 | 14.9 |
| Ranibizumab | 10 | 12.5 | 12.5 |
| Ipilimumab | 15 | 11.6 | 11.6 |